A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Running, not enrolling · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Key facts

Study ID

NCT02537613

Run by

Dana-Farber Cancer Institute

People needed

54

Starts

2015-12-01

Expected to finish

2027-01-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma as per IW-CLL 2008 criteria and require therapy based on meeting at least one of the following criteria:
• Evidence of progressive marrow failure with anemia (hemoglobin <11.0 g/L) and/or thrombocytopenia (platelets <100 x 10\^9/L)
• Massive (≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly
• Massive nodes (at least 10 cm longest diameter), progressive, or symptomatic lymphadenopathy
• Progressive lymphocytosis with an increase of more than 50% over a 2-month period or LDT of <6 months.
• Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids
• Constitutional symptoms, defined as 1 or more of the following:
• unintentional weight loss >10% within 6 months prior to screening
• significant fatigue (inability to work or perform usual activities) fevers >100.5° F or 38.0° C for 2 or more weeks prior to screening without evidence of infection
• night sweats for more than 1 month prior to screening without evidence of infection
• Relapsed after or refractory to at least one prior Chronic Lymphocytic Leukemia-directed therapy
• Age greater than or equal to 18 years
• ECOG Performance Status <2
• Heme criteria at screening, unless significant bone marrow involvement of Chronic Lymphocytic Leukemia confirmed on biopsy:
• Absolute Neutrophil Count (ANC) ≥500 cells/mm3 (0.5 x 10\^9/L). Growth factor allowed to achieve
• Platelet count ≥25,000 cells/mm3 (25 x 10\^9/L) independent of transfusion within 7 days of screening
• Adequate hepatic function defined as: AST and ALT ≤ 4.0 x upper limit of normal (ULN), bilirubin ≤2.0 x upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome)
• Adequate renal function defined by serum creatinine <2.0 x upper limit of normal (ULN) unless due to biopsy proven Chronic Lymphocytic Leukemia kidney infiltration
• Women of child-bearing potential and men must agree to use adequate contraception
• Patients who have undergone prior allo transplant are eligible provided that their transplant day 0 is > 6 months from their first dose of study drug

You may not qualify if…

• History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
• Prior treatment with either obinutuzumab or ibrutinib
• History of other malignancies, except:
• Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
• Adequately treated carcinoma in situ without evidence of disease.
• Low-risk prostate cancer on active surveillance
• Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of >20 mg/day of prednisone) within 28 days of the first dose of study drug.
• Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
• Recent infection requiring systemic treatment that was completed ≤7 days before the first dose of study drug.
• Known bleeding disorders or hemophilia.
• History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
• Known history of HIV or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
• Any uncontrolled active systemic infection.
• Major surgery within 4 weeks of first dose of study drug.
• Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 CHF as defined by the NYHA Functional Classification; or a history of Myocardial Infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
• Lactating or pregnant.
• Patients receiving any other study agents
• Patients with known Central Nervous System involvement
• Baseline QT Interval Corrected by the Fridericia Correction Formula (QTcF) >480 ms unless Left Bundle Branch Block
• Patients who require warfarin or other vitamin K antagonists for anticoagulation
• Concurrent administration of strong inhibitors or inducers of CYP3A

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Rochester Wilmot Cancer Inst. — Rochester, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.